Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-ofseason results

Eurosurveillance

Volumn 21, Issue 38, 2016, Pages

  Pebody, Richard ^a   Warburton, F ^a   Ellis, J ^a   Andrews, N ^a   Potts, A ^b   Cottrell, S ^c   Johnston, J ^d   Reynolds, A ^b   Gunson, R ^e   Thompson, C ^a   Galiano, M ^a   Robertson, C ^f   Byford, R ^g   Gallagher, N ^d   Sinnathamby, M ^a   Yonova, I ^g,h   Pathirannehelage, S ^g   Donati, M ^a   Moore, C ^c   de Lusignan, S ^g,h   McMenamin, J ^b   Zambon, M ^a   more..

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c PUBLIC HEALTH WALES   (United Kingdom)

^d PUBLIC HEALTH AGENCY   (United Kingdom)

^e West of Scotland Specialist Virology Laboratory Gartnavel   (United Kingdom)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^g UNIVERSITY OF SURREY   (United Kingdom)

^h ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; HEMAGGLUTINATION INHIBITION; HIGH THROUGHPUT SEQUENCING; HUMAN; INFANT; INFLUENZA; MALE; MIDDLE AGED; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; UNITED KINGDOM; VACCINATION; CASE CONTROL STUDY; DISEASE OUTBREAKS; EPIDEMIOLOGY; HEALTH SURVEY; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA B VIRUS; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; LABORATORY; PREVENTIVE HEALTH SERVICE; PRIMARY HEALTH CARE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASON; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LABORATORIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; PRIMARY HEALTH CARE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEASONS; UNITED KINGDOM; VACCINATION; VACCINE POTENCY; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84990876511     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.38.30348     Document Type: Article

References (26)

1. Hakin B, Cosford P, Harvey F. The flu immunisation programme 2013/14 - extension to children. London: Department of Health; 26 Jul 2013. Available from: https://www.gov.uk/ government/uploads/system/uploads/attachment_data/ file/225360/Children_s_flu_letter_2013.pdf
2. Public Health England (PHE). Flu plan. Winter 2015/16. London: PHE; May 2016. Available from: https://www.gov. uk/government/uploads/system/uploads/attachment_data/ file/526143/Flu_Plan_Winter_2015_to_2016superseded.pdf
3. Centers for Disease Control and Prevention (CDC). ACIP votes down use of LAIV for 2016-2017 flu season. Media statement. Atlanta: CDC; 22 Jun 2016. Available from: http://www.cdc.gov/ media/releases/2016/s0622-laiv-flu.html
4. Public Health England (PHE). Surveillance of influenza and other respiratory viruses in the United Kingdom: Winter 2015 to 2016. London: PHE; 17 Mar 2016. Available from: https://www. gov.uk/government/uploads/system/uploads/attachment_ data/file/526405/Flu_Annual_Report_2015_2016.pdf
5. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. Euro Surveill. 2016; 21(13): 30179. DOI: 10.2807/1560-7917. ES.2016.21.13.30179 PMID: 27074651
6. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health. 2010; 64(12): 1062-7. DOI: 10.1136/jech.2009.093450 PMID: 19910645
7. Andrews N, McMenamin J, Durnall H, Ellis J, Lackenby A, Robertson C, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill. 2014; 19(27): 20851. DOI: 10.2807/1560-7917.ES2014.19.27.20851 PMID: 25033051
8. Ellis J, Iturriza M, Allen R, Bermingham A, Brown K, Gray J, et al. Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Euro Surveill. 2009; 14(22): 19230. PMID: 19497254
9. Gunson R, Maclean A, Davies E, Bennett S, Miller R, Carman WF. Development of a multiplex real-time RT-PCR that allows universal detection of influenza A viruses and simultaneous typing of influenza A/H1N1/2009 virus. J Virol Methods. 2010; 163(2): 258-61. DOI: 10.1016/j.jviromet.2009.10.006 PMID: 19854220
10. Galiano M, Agapow P-M, Thompson C, Platt S, Underwood A, Ellis J, et al. Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS One. 2011; 6(8): e23779. DOI: 10.1371/journal.pone.0023779 PMID: 21887318
11. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003; 77(15): 8418-25. DOI: 10.1128/JVI.77.15.8418-8425.2003 PMID: 12857911
12. Zambon M. Laboratory Diagnosis of Influenza. In: Nicholson K, Hay A, Webster RG, editors. Textbook of Influenza. Oxford: Blackwell Science; 1998. pp. 291-313].
13. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6. 0.Mol Biol Evol. 2013; 30(12): 2725-9. DOI: 10.1093/molbev/mst197 PMID: 24132122
14. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill. 2011; 16(6): 19791. PMID: 21329644
15. Kissling E, Valenciano M. Early influenza vaccine effectiveness results 2015-16: I-MOVE multicentre case-control study. Euro Surveill. 2016; 21(6): 30134. DOI: 10.2807/1560-7917. ES.2016.21.6.30134 PMID: 26898240
16. Chambers C, Skowronski D, Sabaiduc S, Winter A, Dickinson J, De Serres G, et al. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill. 2016; 21(11): 30168.
17. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016-17 northern hemisphere influenza season. Geneva: WHO; 25 February 2016. Available from: http://www.who.int/influenza/vaccines/virus/ recommendations/2016_17_north/en
18. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015; 211(10): 1529-40. DOI: 10.1093/ infdis/jiu647 PMID: 25406334
19. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016; 21(7): 30139. DOI: 10.2807/1560-7917.ES.2016.21.7.30139 PMID: 26924024
20. Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine. 2016; 34(1): 77-82. DOI: 10.1016/j.vaccine.2015.11.010 PMID: 26589519
21. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill. 2016; 21(38): 30346. DOI: 10.2807/1560-7917. ES.2016.21.38.30346
22. Bandell A, Woo J, Coelingh K. Protective efficacy of liveattenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines. 2011; 10(8): 1131-41. DOI: 10.1586/erv.11.73 PMID: 21854309
23. Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro Surveill. 2015; 20(39): 30029. DOI: 10.2807/1560-7917. ES.2015.20.39.30029 PMID: 26537222
24. Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill. 2014; 19(22): 20823. DOI: 10.2807/1560-7917. ES2014.19.22.20823 PMID: 24925457
25. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016; 21(16): 30201. DOI: 10.2807/1560-7917.ES.2016.21.16.30201 PMID: 27124420
26. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007; 36(3): 623-31. DOI: 10.1093/ije/dym021 PMID: 17403908